Antihypertensive Drugs Removed by Dialysis_ Implications for Management

Antihypertensive Drugs Removed by Dialysis: Implications for Management

The management of hypertension in patients undergoing dialysis presents unique challenges, particularly due to the altered pharmacokinetics of antihypertensive drugs in end-stage renal disease (ESRD) and their potential removal during dialysis sessions. Understanding which antihypertensive drugs are significantly removed by dialysis is crucial for maintaining effective blood pressure control in this patient population. This article will discuss the antihypertensive drugs that are removed by dialysis and the implications for their use in dialysis patients.

Factors affecting drug removal during dialysis:

Molecular weight

Protein binding

Volume of distribution

Water solubility

Dialysis membrane characteristics

Blood and dialysate flow rates

Antihypertensive drugs significantly removed by dialysis:

Beta-blockers:

Atenolol: Highly removed by dialysis due to its low protein binding and primarily renal excretion.

Metoprolol: Moderately removed by dialysis, though less than atenolol.

Nadolol: Significantly removed by dialysis.

Implications: Dose adjustments or administration after dialysis may be necessary to maintain therapeutic effect.

<ol start=”2”>

ACE inhibitors:

Captopril: Significantly removed by dialysis due to its low molecular weight and low protein binding.

Enalapril: Moderately removed by dialysis.

Implications: These drugs may require post-dialysis supplementation to maintain their antihypertensive effect.

<ol start=”3”>

Calcium Channel Blockers:

Nicardipine: Moderately removed by dialysis.

Nifedipine: Some removal during dialysis, though less significant than nicardipine.

Implications: While removal is not as substantial as with other classes, dose adjustments may still be necessary for some patients.

<ol start=”4”>

Alpha-blockers:

Prazosin: Moderately removed by dialysis.

Implications: May require dose adjustment or post-dialysis administration.

<ol start=”5”>

Centrally acting agents:

Clonidine: Moderately removed by dialysis, especially during high-flux dialysis.

Methyldopa: Significantly removed by dialysis.

Implications: These drugs may require post-dialysis dosing to maintain their antihypertensive effect.

Antihypertensive drugs minimally affected by dialysis:

Angiotensin Receptor Blockers (ARBs):

Losartan, Valsartan, Irbesartan: Minimally removed by dialysis due to high protein binding.

<ol start=”2”>

Calcium Channel Blockers:

Amlodipine: Minimally removed by dialysis due to high protein binding and large volume of distribution.

<ol start=”3”>

Beta-blockers:

Carvedilol: Minimally removed by dialysis due to high protein binding and hepatic metabolism.

<ol start=”4”>

Alpha-blockers:

Doxazosin: Minimally removed by dialysis.

<ol start=”5”>

Vasodilators:

Hydralazine: Minimally removed by dialysis.

Minoxidil: Minimally removed by dialysis.

Implications for management:

Timing of administration: For drugs significantly removed by dialysis, administration after dialysis sessions can help maintain therapeutic levels.

Dose adjustments: Higher doses or more frequent dosing may be necessary for drugs removed by dialysis to maintain efficacy.

Monitoring: Regular blood pressure monitoring, both pre- and post-dialysis, is essential to ensure adequate control.

Drug selection: Preferring drugs that are minimally affected by dialysis can simplify management and improve consistency in blood pressure control.